CDK4 and breast carcinoma: Among them, ribociclib, a CDK4/6 inhibitor, in combination with endocrine therapy (ET), has been shown to improve progression-free survival14–16 and overall survival17–19 over single agent ET in patients with metastatic HR+/HER2− breast cancer, including Luminal B disease20,21.